by Generic Drugs Market size is expected to grow Usd 675.29 bn by 2030 at a CAGR of 5.7% over the forecast period 2021 – 2030.
A new study on the global Generic Drugs market has been published by Precedence Research. It presents a wealth of information on key market dynamics, including the drivers, market trends, and challenges, as well as the structure of the global Generic Drugs market. The study offers valuable information about the global Generic Drugs market to illustrate how the market would grow during the forecast period 2021-2030. The report provides the value and volume of the global Generic Drugs market for the period 2021–2030, considering 2019 as the base year and 2030 as the forecast year. The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study.
Key indicators of market growth, which include value chain as well as supply chain analyses, and Compound Annual Growth Rate (CAGR), are elucidated in the study in a comprehensive manner. This data can help readers interpret quantitative growth aspects of the global Generic Drugs market during the forecast period.
Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1205
An extensive analysis on business strategies of leading market players is also featured in study on the global Generic Drugs market. This can help readers understand principal factors to foresee growth in the global Generic Drugs market. In this study, readers can also find specific data on the qualitative and quantitative growth avenues for the global market, which is expected to guide market players in making apt decisions in the future.
The report also delves into the competition landscape of the global Generic Drugs market. Key players operating in the global market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global market report.
Key Players
- Mylan N.V.
- Abbott Laboratories
- ALLERGAN
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- STADA Arzneimittel AG
- GlaxoSmithKline Plc.
- Baxter International Inc.
- Pfizer Inc.
- Sandoz International GmbH
Key Questions Answered in Generic Drugs Market Study
– What are the key factors influencing the Generic Drugs market in each region?
– What will be the CAGR of the global Generic Drugs market between 2017 and 2030?
– What is the future scope and changing trends in technologies in the global Generic Drugs market?
– Which factors will impede the growth of the global Generic Drugs market during the forecast period?
– Which are the leading companies in the global Generic Drugs market?
– Which region is set to expand at the fastest CAGR during the forecast period?
– What is the volume (Units) of different Generic Drugs across all regions during the forecast period?
– Which segment will have the highest revenue globally in 2030 and which segment will expand at the fastest CAGR during the forecast period?
Get Customization on this Research Report@ https://www.precedenceresearch.com/sample/1205
Research Methodology
A unique research methodology has been utilized by precedence research to conduct a comprehensive research on the growth of the global Generic Drugs market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary sources referred to by analysts during the production of the global Generic Drugs market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from Generic Drugs industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped in making precedence research estimates on the future prospects of the global market more reliable and accurate.
Segmentation
By Drug Type
- Simple Generics
- Super Generics
By Brand
- Pure generic drugs
-
- Branded generic drugs
By Route of Drug Administration
- Oral
- Topical
- Parental
- Others
By Therapeutic Application
- Central nervous system (CNS)
- Cardiovascular
- Dermatology
- Oncology
- Respiratory
- Others
Key Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Others
By Geography
- North America
-
-
- U.S.
- Canada
-
- Europe
-
-
- Germany
- France
- United Kingdom
- Rest of Europe
-
- Asia Pacific
-
-
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
-
- Latin America
-
-
- Brazil
- Rest of Latin America
-
- Middle East & Africa (MEA)
-
-
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
-
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Generic Drugs Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on Generic Drugs Market
5.1. Covid-19: generic drugs Industry Impact
5.2. generic drugs Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and generic drugs Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for generic drugs Market Players to deal with Covid-19 Pandemic Scenario
Chapter 6. Generic Drugs Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. The low cost of generics, as an alternative to branded drugs
6.1.1.2. Large number of patent expired branded drugs
6.1.1.3. Initiatives by governments and other regulatory bodies
6.1.2. Market Restraints
6.1.2.1. Stringent governmental regulations and adverse effects associated with drugs
6.1.3. Market Opportunities
6.1.3.1. Use of RPA to ensure regulatory and standards compliance
Chapter 7. Global Generic Drugs Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. generic drugs Market Revenue by Market Players (2017 – 2020)
7.1.1.2. generic drugs Market Revenue Market Share by Market Players (2017 – 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users
Chapter 8. Global Generic Drugs Market, By Drug Type
8.1. generic drugs Market, by Drug Type, 2017-2030
8.1.1. Simple Generics
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Super Generics
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Generic Drugs Market, By Brand
9.1. generic drugs Market, by Brand, 2017-2030
9.1.1. Pure generic drugs
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Branded generic drugs
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Generic Drugs Market, By Route of Drug Administration
10.1. generic drugs Market, by Route of Drug Administration, 2017-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Parental
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Generic Drugs Market, By Therapeutic Application
11.1. generic drugs Market, by Therapeutic Application, 2017-2030
11.1.1. Central nervous system (CNS)
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Dermatology
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Oncology
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Respiratory
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Generic Drugs Market, By Distribution Channel
12.1. generic drugs Market, by Distribution Channel, 2017-2030
12.1.1. Hospitals Pharmacies
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Retail Pharmacies
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Others
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Generic Drugs Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue Forecast by Drug Type(2017-2030)
13.1.2. Market Revenue Forecast by Brand (2017-2030)
13.1.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.1.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.1.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.1.6. U.S
13.1.6.1. Market Revenue Forecast (2017-2030)
13.1.7. Canada
13.1.7.1. Market Revenue Forecast (2017-2030)
13.2. Europe
13.2.1. Market Revenue Forecast by Drug Type (2017-2030)
13.2.2. Market Revenue Forecast by Brand (2017-2030)
13.2.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.2.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.2.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue Forecast (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue Forecast (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue Forecast (2017-2030)
13.2.9. Rest of EU
13.2.9.1. Market Revenue Forecast (2017-2030)
13.3. Asia Pacific (APAC)
13.3.1. Market Revenue Forecast by Drug Type (2017-2030)
13.3.2. Market Revenue Forecast by Brand (2017-2030)
13.3.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.3.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.3.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.3.6. China
13.3.6.1. Market Revenue Forecast (2017-2030)
13.3.7. India
13.3.7.1. Market Revenue Forecast (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue Forecast (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue Forecast (2017-2030)
13.4. LATAM
13.4.1. Market Revenue Forecast by Drug Type (2017-2030)
13.4.2. Market Revenue Forecast by Brand (2017-2030)
13.4.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.4.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.4.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.4.6. Brazil
13.4.6.1. Market Revenue Forecast (2017-2030)
13.4.7. Rest of LATAM
13.4.7.1. Market Revenue Forecast (2017-2030)
13.5. Middle East and Africa (MEA)
13.5.1. Market Revenue Forecast by Drug Type (2017-2030)
13.5.2. Market Revenue Forecast by Brand (2017-2030)
13.5.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)
13.5.4. Market Revenue Forecast by Therapeutic Application (2017-2030)
13.5.5. Market Revenue Forecast by Distribution Channel (2017-2030)
13.5.6. GCC
13.5.6.1. Market Revenue Forecast (2017-2030)
13.5.7. North Africa
13.5.7.1. Market Revenue Forecast (2017-2030)
13.5.8. South Africa
13.5.8.1. Market Revenue Forecast (2017-2030)
13.5.9. Rest of MEA
13.5.9.1. Market Revenue Forecast (2017-2030)
Chapter 14. Company Profiles
14.1. Abbott Laboratories
14.1.1. Company Overview, Business Information, Regional Presence
14.1.2. Product Portfolio Analysis
14.1.2.1. Product Details, Specification, Application
14.1.3. Revenue, Price, and Gross Margin (2017-2020)
14.1.4. Recent Developments and Strategies
14.2. Teva Pharmaceutical Industries Ltd.
14.2.1. Company Overview, Business Information, Regional Presence
14.2.2. Product Portfolio Analysis
14.2.2.1. Product Details, Specification, Application
14.2.3. Revenue, Price, and Gross Margin (2017-2020)
14.2.4. Recent Developments and Strategies
14.3. ALLERGAN
14.3.1. Company Overview, Business Information, Regional Presence
14.3.2. Product Portfolio Analysis
14.3.2.1. Product Details, Specification, Application
14.3.3. Revenue, Price, and Gross Margin (2017-2020)
14.3.4. Recent Developments and Strategies
14.4. Sandoz International GmbH
14.4.1. Company Overview, Business Information, Regional Presence
14.4.2. Product Portfolio Analysis
14.4.2.1. Product Details, Specification, Application
14.4.3. Revenue, Price, and Gross Margin (2017-2020)
14.4.4. Recent Developments and Strategies
14.5. Mylan N.V.
14.5.1. Company Overview, Business Information, Regional Presence
14.5.2. Product Portfolio Analysis
14.5.2.1. Product Details, Specification, Application
14.5.3. Revenue, Price, and Gross Margin (2017-2020)
14.5.4. Recent Developments and Strategies
14.6. STADA Arzneimittel AG
14.6.1. Company Overview, Business Information, Regional Presence
14.6.2. Product Portfolio Analysis
14.6.2.1. Product Details, Specification, Application
14.6.3. Revenue, Price, and Gross Margin (2017-2020)
14.6.4. Recent Developments and Strategies
14.7. Baxter International Inc.
14.7.1. Company Overview, Business Information, Regional Presence
14.7.2. Product Portfolio Analysis
14.7.2.1. Product Details, Specification, Application
14.7.3. Revenue, Price, and Gross Margin (2017-2020)
14.7.4. Recent Developments and Strategies
14.8. Eli Lilly and Company
14.8.1. Company Overview, Business Information, Regional Presence
14.8.2. Product Portfolio Analysis
14.8.2.1. Product Details, Specification, Application
14.8.3. Revenue, Price, and Gross Margin (2017-2020)
14.8.4. Recent Developments and Strategies
14.9. GlaxoSmithKline Plc.
14.9.1. Company Overview, Business Information, Regional Presence
14.9.2. Product Portfolio Analysis
14.9.2.1. Product Details, Specification, Application
14.9.3. Revenue, Price, and Gross Margin (2017-2020)
14.9.4. Recent Developments and Strategies
14.10. Pfizer Inc.
14.10.1. Company Overview, Business Information, Regional Presence
14.10.2. Product Portfolio Analysis
14.10.2.1. Product Details, Specification, Application
14.10.3. Revenue, Price, and Gross Margin (2017-2020)
14.10.4. Recent Developments and Strategies
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Get Full Access of this Research Report, Click here@ https://www.precedenceresearch.com/checkout/1205
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
